Shares of InMode Ltd. (NASDAQ:INMD – Get Free Report) have earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.00.
Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a report on Thursday, August 6th.
View Our Latest Stock Report on InMode
Hedge Funds Weigh In On InMode
InMode Trading Up 0.9%
Shares of NASDAQ INMD opened at $14.90 on Thursday. The stock has a 50 day simple moving average of $15.07 and a 200-day simple moving average of $14.28. The company has a market cap of $856.45 million, a PE ratio of 12.11 and a beta of 1.86. InMode has a 12-month low of $12.72 and a 12-month high of $16.74.
InMode (NASDAQ:INMD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.35. InMode had a return on equity of 11.99% and a net margin of 20.69%.The business had revenue of $95.59 million during the quarter, compared to analyst estimates of $94.89 million. During the same period in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year.
About InMode
InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.
InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.
The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.
See Also
- Five stocks we like better than InMode
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
